| Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells. | sarcoma, |
| The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma. | sarcoma, |
| Novel oncogenic mutations in the WT1 Wilms tumor suppressor gene: a t(11;22) fuses the Ewing s sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor. | sarcoma, |
| An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. | None |
| Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. | None |
| Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. | None |
| An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene. | None |
| Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. | None |
| A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene. | None |
| The AF2 domain of the orphan nuclear receptor TEC is essential for the transcriptional activity of the oncogenic fusion protein EWS | None |
| The AF2 domain of the orphan nuclear receptor TEC is essential for the transcriptional activity of the oncogenic fusion protein EWS/TEC. | None |
| Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. | None |
| Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. | None |
| EWS interacts with FLI1 and their oncogenic fusion protein. | None |
| Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. | None |
| The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1. | None |
| The oncogenic fusion protein EWS/NOR-1 induces transformation of CFK2 chondrogenic cells. | None |
| EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. | None |
| Recombinant EWS-FLI1 oncoprotein activates transcription. | None |
| RGG-boxes of the EWS oncoprotein repress a range of transcriptional activation domains. | None |